Sun Pharma launches FluGuard to treat mild to moderate COVID-19 disease

Sun Pharmaceutical Industries Limited (Sun Pharma) informed the bourses on Tuesday that the company has launched FluGuard (Favipiravir 200 mg).

The company has launched this medicine at a very affordable price i.e. Rs 35 per tablet. It will be used to treat patients having a mild to moderate COVID-19 disease. The stocks of FluGuard would be available in the market, starting this week.

Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate COVID-19 disease.

Glenmark Pharma was the first company, which had received regulatory approval for Favipiravir last month. Glenmark has cut down the price of the tablet from Rs 103 to Rs 75.

However, it is to be noted that Favipiravir has not been added to the Ministry of Health’s Clinical Management Protocol due to the lack of enough clinical benefit evidence.  

Today, the stock of Sun Pharma gained nearly 2 per cent and made an intraday high of Rs 532.15 on BSE.